^
    2d
    Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network. (PubMed, ESMO Open)
    This multicentre study confirms that anthracycline-based regimens show activity in MCS, with responses more in line with soft tissue sarcoma than Ewing sarcoma. Their benefit in localized disease remains uncertain, but (neo)adjuvant chemotherapy with Ewing-like regimens should be considered for patients eligible for surgery. In advanced disease, trabectedin may provide prolonged disease control after anthracyclines.
    Retrospective data • Journal
    |
    HEY1 (Hes Related Family BHLH Transcription Factor With YRPW Motif 1) • NCOA2 (Nuclear Receptor Coactivator 2)
    |
    ifosfamide • Yondelis (trabectedin)
    2d
    ePPS-2202: Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment. (clinicaltrials.gov)
    P=N/A, N=377, Recruiting, Centre Oscar Lambret | Trial completion date: Mar 2028 --> Apr 2030 | Trial primary completion date: Jun 2026 --> Jul 2028
    Trial completion date • Trial primary completion date • Head-to-Head
    2d
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Washington University School of Medicine | Phase classification: P1/2 --> P1 | N=35 --> 6 | Trial completion date: Jan 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Mar 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    ifosfamide • Hepacid (pegargiminase) • mesna
    2d
    Malignant nodular fasciitis, a rare manifestation of a benign disease: case report. (PubMed, Front Oncol)
    She subsequently received systemic therapy, initially with temozolomide and later pazopanib, followed by sunitinib. This case illustrates the importance of molecular drivers of cancer in a benign soft-tissue tumor and the potential to offer targeted therapies to extend patient survival. This rare case highlights the potential malignant behavior of nodular fasciitis associated with PPP6R3-USP6 fusion.
    Journal
    |
    USP6 (Ubiquitin Specific Peptidase 6)
    |
    sunitinib • temozolomide • pazopanib
    3d
    Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma. (PubMed, Clin Cancer Res)
    This study identifies ADORA2B as a critical regulator of metastatic progression in UPS, implicating it as a promising therapeutic target. Ongoing clinical trials targeting adenosine pathways further support the translational potential of ADORA2B inhibition to disrupt metastasis and improve outcomes for UPS patients.
    Journal
    |
    ADORA2B (Adenosine A2b Receptor)
    4d
    Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas (clinicaltrials.gov)
    P=N/A, N=98, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    4d
    Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards. (PubMed, J Transl Med)
    This study demonstrates the feasibility and clinical utility of integrating genomic-driven precision oncology with PDOX-based functional testing for MPNSTs. This strategy may support molecular tumor boards (MTBs) in their treatment decisions. The observed genomic stability supports the use of longitudinal tumor profiling to guide treatment, and the success of MEKi+BETi highlights its potential as a combination therapy for MPNSTs.
    Journal
    |
    NF1 (Neurofibromin 1)
    4d
    SarcAblate: HIFU Ablation of Soft Tissue Sarcoma (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Oxford University Hospitals NHS Trust | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    5d
    SB101: Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Sonnet BioTherapeutics | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    SON-1010
    6d
    68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    6d
    Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2023 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    6d
    Mammary malignant peripheral nerve sheath tumor in a 93-year-old male: case report. (PubMed, J Surg Case Rep)
    The patient underwent a right mastectomy, achieving a surgical clearance. After 3 months, he passed away with malignant pleural effusion due to lung metastasis.
    Journal
    |
    VIM (Vimentin) • TP63 (Tumor protein 63)